Dubin Arnaldo, Murias Gastón, Sottile Juan Pablo, Pozo Mario Omar, Barán Marcelo, Edul Vanina Siham Kanoore, Canales Héctor Saúl, Etcheverry Graciela, Maskin Bernardo, Estenssoro Elisa
Cátedra de Farmacología, Facultad de Ciencias Médicas, Universidad Nacional de La Plata, 42 No 577, 1900, La Plata, Argentina.
Intensive Care Med. 2007 Mar;33(3):485-94. doi: 10.1007/s00134-006-0519-5. Epub 2007 Jan 30.
To test the hypothesis that levosimendan increases systemic and intestinal oxygen delivery (DO(2)) and prevents intramucosal acidosis in septic shock.
Prospective, controlled experimental study.
University-based research laboratory.
Nineteen anesthetized, mechanically ventilated sheep.
Endotoxin-treated sheep were randomly assigned to three groups: control (n=7), dobutamine (10 microg/kg/min, n=6) and levosimendan (100 microg/kg over 10 min followed by 100 microg/kg/h, n=6) and treated for 120 min.
After endotoxin administration, systemic and intestinal DO(2) decreased (24.6+/-5.2 vs 15.3+/-3.4 ml/kg/min and 105.0+/-28.1 vs 55.8+/-25.9 ml/kg/min, respectively; p<0.05 for both). Arterial lactate and the intramucosal-arterial PCO(2) difference (DeltaPCO(2)) increased (1.4+/-0.3 vs 3.1+/-1.5 mmHg and 9+/-6 vs 23+/-6 mmHg mmol/l, respectively; p<0.05). Systemic DO(2) was preserved in the dobutamine-treated group (22.3+/-4.7 vs 26.8+/-7.0 ml/min/kg, p=NS) but intestinal DO(2) decreased (98.9+/-0.2 vs 68.0+/-22.9 ml/min/kg, p<0.05) and DeltaPCO(2) increased (12+/-5 vs 25+/-11 mmHg, p<0.05). The administration of levosimendan prevented declines in systemic and intestinal DO(2) (25.1+/-3.0 vs 24.0+/-6.3 ml/min/kg and 111.1+/-18.0 vs 98.2+/-23.1 ml/min/kg, p=NS for both) or increases in DeltaPCO(2) (7+/-7 vs 10+/-8, p=NS). Arterial lactate increased in both the dobutamine and levosimendan groups (1.6+/-0.3 vs 2.5+/-0.7 and 1.4+/-0.4 vs. 2.9+/-1.1 mmol/l, p=NS between groups).
Compared with dobutamine, levosimendan increased intestinal blood flow and diminished intramucosal acidosis in this experimental model of sepsis.
验证左西孟旦可增加全身和肠道氧输送(DO₂)并预防脓毒性休克时肠黏膜内酸中毒这一假说。
前瞻性对照实验研究。
大学研究实验室。
19只麻醉、机械通气的绵羊。
经内毒素处理的绵羊随机分为三组:对照组(n = 7)、多巴酚丁胺组(10微克/千克/分钟,n = 6)和左西孟旦组(10分钟内给予100微克/千克,随后100微克/千克/小时,n = 6),并治疗120分钟。
给予内毒素后,全身和肠道DO₂降低(分别为24.6±5.2对15.3±3.4毫升/千克/分钟和105.0±28.1对55.8±25.9毫升/千克/分钟;两者p均<0.05)。动脉血乳酸和肠黏膜-动脉血二氧化碳分压差值(ΔPCO₂)升高(分别为1.4±0.3对3.1±1.5毫米汞柱和9±6对23±6毫米汞柱毫摩尔/升;p<0.05)。多巴酚丁胺治疗组全身DO₂得以维持(22.3±4.7对26.8±7.0毫升/分钟/千克,p无统计学意义),但肠道DO₂降低(98.9±0.2对68.0±22.9毫升/分钟/千克,p<0.05)且ΔPCO₂升高(12±5对25±11毫米汞柱,p<0.05)。给予左西孟旦可预防全身和肠道DO₂下降(25.1±3.0对24.0±6.3毫升/分钟/千克和111.1±18.0对98.2±23.1毫升/分钟/千克,两者p均无统计学意义)或ΔPCO₂升高(7±7对10±8,p无统计学意义)。多巴酚丁胺组和左西孟旦组动脉血乳酸均升高(1.6±0.3对2.5±0.7和1.4±0.4对2.9±1.1毫摩尔/升,两组间p无统计学意义)。
在该脓毒症实验模型中,与多巴酚丁胺相比,左西孟旦增加了肠道血流量并减轻了肠黏膜内酸中毒。